Key Figures

In T€2016 2015 change
RESULTS OF OPERATIONS
Total revenue9,7496,80843%
Revenue Veregen®  3,0483,101 -2% 
Revenue from the cooperation with bluebird1,0530
Other operating income 5,6483,707 52%
     thereof gain on sale on intangible assets, net 2,3650
Cost of sales -1,402-1,103 27%
Gross profit 8,3475,705 46%
Selling and general administrative expenses -10,025-7,615 32%
Research and development expenses -11,538-8,529 35%
     thereof immunotherapies-10,468-5,53489%
Operating result -13,216-10,439 27%
Income from the sale of financial assets4,2420
Net profit/loss for the year -9,492-12,999 -27%
EBITDA -12,371-9,495 30%
Earnings per share (basic/diluted) (€) -0.48-0.77 -38%
Personnel expenses -9,493-7,664 24%
CASH FLOWS
Net cash used in operating activities -3,758-10,605 -65%
Net cash from / used in investing activities 9,860-39,409  -125%
Net cash used / from financing activities -23143,797 -101%
BALANCE SHEET
Cash and cash equivalents and time deposits 52,63046,759 13%
Total assets 111,715113,531 -2%
Current liabilities 11,9669,664 24%
Non-current liabilities 21,15713,879 52%
Shareholders' equity 78,59289,988 -13%
Equity ratio (%) 70 79 -11%
Employees as at 31 December 887321%
FTEs as at 31 December 806621%
MEDIGENE SHARE
Total number of shares outstanding as at December 3120,136,88719,678,628 2%
Share price (XETRA closing price) as at December 31 (€) 11.908.7037%
Dividend (€) 0 0